Literature DB >> 18829681

Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia.

A S Naura1, R Datta, C P Hans, M Zerfaoui, B M Rezk, Y Errami, M Oumouna, K Matrougui, A H Boulares.   

Abstract

Inducible nitric oxide synthase (iNOS) inhibition was recently shown to exert no effect on allergen challenge in human asthma, raising serious concerns about the role of the protein in the disease. The present study investigated the role of iNOS in ovalbumin-induced eosinophilia from the perspective of its relationship with poly(ADP-ribose) polymerase-1 (PARP-1) and oxidative DNA damage. A mouse model of ovalbumin-induced eosinophilia was used to conduct the studies. iNOS-associated protein nitration and tissue damage were partially responsible for allergen-induced eosinophilia. iNOS expression was required for oxidative DNA damage and PARP-1 activation upon allergen challenge. PARP-1 was required for iNOS expression and protein nitration, and this requirement was connected to nuclear factor-kappaB. PARP-1 was an important substrate for iNOS-associated by-products after ovalbumin-challenge. PARP-1 nitration blocked its poly(ADP-ribosyl)ation activity. Interleukin-5 re-establishment in ovalbumin-exposed PARP-1(-/-) mice reversed eosinophilia and partial mucus production without a reversal of iNOS expression, concomitant protein nitration or associated DNA damage. The present results demonstrate a reciprocal relationship between inducible nitric oxide synthase and poly(ADP-ribose) polymerase-1 and suggest that expression of inducible nitric oxide synthase may be dispensable for eosinophilia after interleukin-5 production. Inducible nitric oxide synthase may be required for oxidative DNA damage and full manifestation of mucus production. Such dispensability may explain, in part, the reported ineffectiveness of inducible nitric oxide synthase inhibition in preventing allergen-induced inflammation in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829681     DOI: 10.1183/09031936.00089008

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.

Authors:  R Datta; A S Naura; M Zerfaoui; Y Errami; M Oumouna; H Kim; J Ju; V P Ronchi; A L Haas; A H Boulares
Journal:  Allergy       Date:  2011-01-28       Impact factor: 13.146

2.  PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.

Authors:  Kunal Kapoor; Esha Singla; Bijayani Sahu; Amarjit S Naura
Journal:  Mol Cell Biochem       Date:  2014-11-18       Impact factor: 3.396

3.  Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.

Authors:  Hogyoung Kim; Amarjit S Naura; Youssef Errami; Jihang Ju; A Hamid Boulares
Journal:  Mol Med       Date:  2011-05-13       Impact factor: 6.354

4.  Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation.

Authors:  Mourad Zerfaoui; Youssef Errami; Amarjit S Naura; Yasuhiro Suzuki; Hogyoung Kim; Jihang Ju; Tao Liu; Chetan P Hans; Jong G Kim; Zakaria Y Abd Elmageed; Shahriar Koochekpour; Andrew Catling; A Hamid Boulares
Journal:  J Immunol       Date:  2010-07-07       Impact factor: 5.422

Review 5.  Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health.

Authors:  Carlos W Nossa; Steven R Blanke
Journal:  Gut Microbes       Date:  2010 Nov-Dec

Review 6.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

7.  Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy Antigen Receptor for Chemokines.

Authors:  Mourad Zerfaoui; Amarjit S Naura; Youssef Errami; Chetan P Hans; Bashir M Rezk; Jiwon Park; Waleed Elsegeiny; Hogyoung Kim; Kevin Lord; Jong G Kim; A Hamid Boulares
Journal:  J Leukoc Biol       Date:  2009-09-10       Impact factor: 4.962

Review 8.  Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability.

Authors:  Hu Wang; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Jong-Hun Lee; Ah-Ng Tony Kong
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

9.  Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase.

Authors:  Amarjit S Naura; Hogyoung Kim; Jihang Ju; Paulo C Rodriguez; Joaquin Jordan; Andrew D Catling; Bashir M Rezk; Zakaria Y Abd Elmageed; Kusma Pyakurel; Abdelmetalab F Tarhuni; Mohammad Q Abughazleh; Youssef Errami; Mourad Zerfaoui; Augusto C Ochoa; A Hamid Boulares
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

10.  Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.

Authors:  Chetan P Hans; Yumei Feng; Amarjit S Naura; Mourad Zerfaoui; Bashir M Rezk; Huijing Xia; Alan D Kaye; Khalid Matrougui; Eric Lazartigues; A Hamid Boulares
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.